Compare Eli Lilly And Co (LLY) vs Wipro Limited (WIT) Price & Performance

Eli Lilly (LLY) trades at $1,150.86, down 2.39% on the day, with a bullish technical signal from moving averages and strong fundamental performance. The company reported robust earnings beats in recent quarters, with Q1 2026 EPS of $8.55 exceeding expectations by 23%. Revenue surged to $65.18 billion in 2025, driving a net income margin of 34.99%. Recent news highlights LLY's $2.8 billion acquisition of AtaiBeckley to expand its neuroscience pipeline, signaling strategic growth in mental health treatments.

Outlook remains positive with analyst consensus price target of $1,380 implying 20% upside, supported by 73% buy ratings. Key risks include high valuation multiples (P/E 41.89) and rising debt levels, though operating cash flow growth to $16.81 billion in 2025 provides financial flexibility. Investors should monitor Q2 2026 earnings on August 5 for continued execution on weight-loss drug demand and integration of recent acquisitions.

WIT trades at $1.855, down 0.27% with bearish technical signals. Recent quarters show earnings misses against expectations, though 2025 revenue was $890.88B with net income of $131.35B. Valuation ratios appear reasonable with P/E of 13.97 and P/B of 1.96. Analyst consensus is mixed with 19% buy ratings amid concerns about client spending and AI investments.

The outlook remains cautious due to earnings volatility and competitive pressures. Investment appeal hinges on AI partnership execution and margin stabilization, while risks include geopolitical uncertainty and tech spending constraints. Cash flow strength provides some buffer against near-term headwinds.